A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients With Chemosensitive Advanced Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PIN
- 24 Oct 2018 Planned primary completion date changed from 1 May 2015 to 1 Dec 2018.
- 24 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2015 Accrual to date is 73% according to the United Kingdom Clinical Research Network record.